# Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation

> **NCT04564313** · PHASE1 · UNKNOWN · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 20 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Transplantation

## Interventions

- **DRUG:** Camrelizumab treatment

## Key facts

- **NCT ID:** NCT04564313
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-21
- **Primary completion:** 2022-09
- **Final completion:** 2023-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564313, "Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04564313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*